STRENGTH WEAKNESS OPPORTUNITY THREATS COMBIFLAM PLUS CROCIN PAIN RELIEF

1. SWOT Analysis
By
VICKY JAIN

2. CROCIN PAIN RELIEF
STRENGTH
Solid brand picture – worldwide nearness in excess of 80
nations
Associated trust with parent organization having
worldwide nearness.
Different plans for various arrangement of purchasers
Strong brand review because of substantial interest in
advancements and promoting
Strong circulation system of GSK
•WEAKNESS
•Although having both antipyretic and pain-relieving
properties for the most part saw and utilized for fever
help (antipyretic) which is a littler fragment of market
than the analgesics.
•Objections from FDA for a portion of its campaigns
tarnished its picture briefly although they were later
sifted through.
•Drug pricing authority forced a fine of approx. 54
crores in 2014.
OPPORTUNITIES:
•Focus on the elective channels and advance
it through medical representatives.
•Advance the pain-relieving benefits more
to tap the massive painkiller market
•THREATS:
•Stringent legal regulations
•Parcel of rivalry in the market.
•Most of the time the druggist has the influencing
power in the sale of OTC products.

3. COMBIFLAM PLUS
Strength
1. Targeted, Fast and effective OTC solution for
headaches.
2. Synergistic effect and adjuvant action.
3. It provides mental clarity.
4. Prevents the suffering from four cognitive
parameters(Attention, reasoning, perception, co-
ordination)
5. No adverse effects on Gut.
6. Innovative packaging with first of its kind(Pack of 4s)
7. Total pain relief with 89% of incremental
analgesic effect compared with paracetamol
monotherapy.
8. In top 100 pharmaceutical brands in India.
9. Growing at CAGR of 7-8% for the last 5 years.
Weakness
1. Nausea
2. Vomiting
Opportunities
1. 7 out of 10 people in India suffer from headache.
2. Digital marketing
3. Due to covid-19, cases of sedentary lifestyle is
increased.
4. Combiflam is an established renowned brand in market
over 25 years.(1 in every 3 household)
Threats
1. People adoption for AYUSH therapy.
2. More potential new drugs.
3. Competitors could leverage brand strength.